Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.

ABSTRACT:

Background

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated to produce significantly greater reduction in LDL cholesterol levels and cardiovascular events than standard statin therapy. However, evidence on the impact of PCSK9 inhibitors on coronary plaque composition and morphology is limited.

Methods

In this open-label randomized study, eligible patients with intermediate coronary lesions and elevated LDL cholesterol values were randomized to either alirocumab 75 mg Q2W plus statin (atorvastatin 20 mg/day or rosuvastatin 10 mg/day) therapy or standard care. Optical coherence tomography (OCT) assessments for target lesions were obtained at baseline and at 36 weeks of follow-up.

Results

LDL cholesterol levels were significantly de

SUBMITTER: Gao F 

PROVIDER: S-EPMC8436513 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature